Interactions between diabetic and hypertensive drugs: a pharmacogenetics approach.

Autor: Ansari, Asma Imran, Rizvi, Aliya Abbas, Verma, Shrikant, Abbas, Mohammad, Siddiqi, Zeba, Mishra, Divakar, Verma, Sushma, Raza, Syed Tasleem, Mahdi, Farzana
Předmět:
Zdroj: Molecular Genetics & Genomics; Jul2023, Vol. 298 Issue 4, p803-812, 10p
Abstrakt: Diabetes is known to increase susceptibility to hypertension due to increase in inflammation, oxidative stress, and endothelial dysfunction, leading to vascular stiffness. The polytherapy might lead to several drug–drug interactions (DDIs), which cause certain life-threatening complications such as diabetic nephropathy and hypoglycaemia. So, in this review we focused on drug–drug interactions and impact of genetic factors on drug responses for better disease management. Drug–drug interactions (DDIs) may act either synergistically or antagonistically. For instance, a combination of metformin with angiotensin II receptor antagonist or angiotensin-converting enzyme inhibitors (ACEIs) synergistically improves glucose absorption, whereas the same hypertensive drug combination with sulphonylurea might cause severe hypoglycaemia sometimes. Thiazolidinediones (TDZs) can cause fluid retention and heart failure when taken alone, but a combination of angiotensin II receptor antagonist with TZDs prevents these side effects. Interindividual genetic variation affects the DDI response. We found two prominent genes, GLUT4 and PPAR-γ, which are common targets for most of the drug. So, all of these findings established a connection between drug–drug interaction and genetics, which might be used for effective disease management. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: